PRNewsWire
19 Jun 2026, 11:30 UTC · 2h ago
Replicate Bioscience Awarded Grant to Advance srRNA Vaccine Candidates for Tuberculosis
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
PRNewsWire
19 Jun 2026, 11:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Replicate Bioscience has been awarded a $3 million research grant from the Gates Foundation to develop tuberculosis vaccine candidates. — Non-dilutive funding from a prestigious organization validates the company's technology and provides capital for R&D.
+0.40The company's srRNA platform has demonstrated protective immunity at lower doses than other mRNA or srRNA vaccines in Phase I rabies trials. — Clinical proof of concept regarding dose efficiency suggests a competitive technological advantage over standard mRNA platforms.
+0.30Replicate Bioscience has established a pipeline of srRNA vaccines for HIV and malaria in addition to the tuberculosis and rabies programs. — A diversifying pipeline reduces single-asset risk and expands the total addressable market for the company's platform.
+0.20Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
1h ago
